Alchemist vs OrganiGram Which Should You Buy?

Alchemist and OrganiGram are two prominent companies in the cannabis industry, both engaged in the cultivation and production of cannabis products. Alchemist focuses on creating high-quality cannabis strains and derivative products, while OrganiGram is known for its innovative approaches to cultivation and extraction. Both companies have seen significant growth in recent years, with Alchemist's stock prices reflecting its strong market presence and OrganiGram's dynamic strategies positioning it as a key player in the industry. Investors looking to capitalize on the booming cannabis market may consider these two stocks as potential options for their investment portfolios.

Alchemist or OrganiGram?

When comparing Alchemist and OrganiGram, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Alchemist and OrganiGram.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Alchemist has a dividend yield of -%, while OrganiGram has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Alchemist reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, OrganiGram reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Alchemist P/E ratio at 152.03 and OrganiGram's P/E ratio at -2.99. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Alchemist P/B ratio is 0.68 while OrganiGram's P/B ratio is 0.74.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Alchemist has seen a 5-year revenue growth of 0.20%, while OrganiGram's is 3.45%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Alchemist's ROE at 0.45% and OrganiGram's ROE at -26.61%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₹21.50 for Alchemist and $1.45 for OrganiGram. Over the past year, Alchemist's prices ranged from ₹4.43 to ₹21.50, with a yearly change of 385.33%. OrganiGram's prices fluctuated between $1.21 and $2.91, with a yearly change of 140.10%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.